Reported Earlier, Moderna And Mitsubishi Tanabe Pharma Partner To Promote MRNA Respiratory Vaccine Portfolio In Japan
Reported Earlier, Moderna And Mitsubishi Tanabe Pharma Partner To Promote MRNA Respiratory Vaccine Portfolio In Japan
早些时候报道，Moderna和三菱田边制药合作推广在日本的mRNA呼吸道疫苗组合。
Under the agreement, Moderna will handle the manufacturing, sales, medical education and distribution of its mRNA respiratory vaccines. Both companies will engage in activities to enable broad access to Moderna's mRNA respiratory portfolio to have the maximum impact on public health in Japan. The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed.
根据协议，Moderna将处理其mRNA呼吸道疫苗的制造、销售、医学教育和分销。两家公司将进行活动，以确保在日本实现广泛接触现代mRNA呼吸道系列作品，并对公众健康产生最大影响。该协议的初步期限为2029年3月31日，未披露有关交易财务条款的进一步详细信息。